Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG
Corinna Kochanek(Medizinische Hochschule Hannover), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Yenny Angela(Johannes Wesling Klinikum Minden), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Sebastian Haferkamp(University Hospital Regensburg), Friedegund Meier(National Center for Tumor Diseases), Julia Welzel(University Hospital Augsburg), Selma Ugurel(Klinikum Bielefeld), Lisa Zimmer(The University of Sydney), P. Dücker(Klinikum Dortmund), Ulrike Leiter(University of Tübingen), Catharina Gilde(Medizinische Hochschule Hannover), Jochen Utikal(German Cancer Research Center), Imke von Wasielewski(Medizinische Hochschule Hannover), Rudolf Herbst(Helios Klinikum Erfurt)
Cited by 7
Related Papers
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways
|Nature Genetics|2009|1.4k